-
2024-510921-25-00
4
2022-03-18
Prosthetic Joint Infection
-
2023-507652-76-00
11
2022-01-02
Infectious endocarditis
-
2024-512612-22-00
5
2021-12-09
Diabetic Foot Ulcer
-
2023-507164-39-00
6
2021-12-01
Induction of labour
-
2024-511651-17-00
4
2021-09-21
Myelodysplastic syndrome
-
2024-512743-23-00
5
2021-08-31
Acute Migraine (with or without aura)
-
2024-512982-15-00
5
2021-06-28
BRCA Mutated Ovarian Cancer Patients, Epithelian ovarian cancer, Metas
-
2023-505483-11-00
6
2021-05-02
Brain abscess
-
2024-517048-67-00
4
2021-04-21
Cerebral commotio
-
2024-512671-12-00
10
2021-03-05
Unresectable head and neck squamous cell carcinoma, metastatic head an
-
2022-501874-21-00
6
2020-12-15
Takotsubo syndrome
-
2023-508722-99-00
4
2020-11-19
Vulvar cancer
-
2024-512526-28-00
5
2020-10-28
Locally recurrent rectal cancer
-
2024-510579-40-00
9
2020-10-07
Rhabdoyosarcoma
-
2024-518384-36-00
4
2020-08-31
Idiopathic membranous nephropathy and severe proteinuria
-
2022-501456-28-00
5
2020-07-20
atypical teratoid/rhabdoid tumours (ATRT)
-
2022-501050-11-01
10
2020-07-13
Acute Lymphoblastic Leukaemia
-
2023-509846-36-00
9
2020-05-29
Advanced Solid Tumors
-
2023-509847-29-00
7
2020-04-09
Advanced solid tumors
-
2022-501454-11-00
5
2020-02-05
standard risk ALK-positive anaplastic large cell lymphoma (ALCL)
-
2023-508101-24-00
5
2019-08-01
Lymphoblastic lymphoma
-
2023-504201-36-00
10
2018-12-21
Defined by parent protocol. The study will enroll all adult and paedia
-
2022-501257-36-00
9
2015-03-19
Treatment of advanced melanoma, or advanced, relapsed or
refractory PD
-
2024-515626-92-00
4
2013-10-18
recurrent/progressive medulloblastoma, ependymoma and atypical teratoi